Search Results
Your search for can matches 13479 pages
Showing 6701 - 6750Expert Point of View: Richard L. Schilsky, MD
“This study shows us that it is possible to get equally good outcomes with lower costs. In the United States, we have no real way to constrain the costs of health care, including the cost of drugs. The U.S. Food and Drug Administration does not consider drug price in deliberations about bringing...
Expert Point of View: Kenneth C. Anderson, MD, FASCO, Adam D. Cohen, MD, Craig Hofmeister, MD, MPH, and Bruce Cheson, MD
Kenneth C. Anderson, MD, FASCO, of Dana-Farber Cancer Institute, Boston, noted that the iNNOVATE trial is the first randomized comparison of ibrutinib (Imbruvica) plus rituximab (Rituxan) vs “a very active control—rituximab—to which 50% of patients responded.” The study showed that “the...
Outcomes in Waldenström’s Macroglobulinemia Improved With Ibrutinib Plus Rituximab
In patients with Waldenström’s macroglobulinemia, the risk of disease progression was reduced by 80% with the combination of ibrutinib (Imbruvica) and rituximab (Rituxan) over rituximab alone, in the international phase III iNNOVATE trial, reported at the 2018 ASCO Annual Meeting1 and...
Expert Point of View: Andrew Epstein, MD
“This is a very important study,” said ASCO expert Andrew Epstein, MD, of Memorial Sloan Kettering Cancer Center (MSK), New York. “Hyperthermic intraperitoneal chemotherapy is used in the United States and elsewhere, even though the benefits are unknown. This study shows there are no benefits, and ...
Less Is More: No Benefit Reported for Hyperthermic Intraperitoneal Chemotherapy in Colorectal Cancer
With a growing emphasis on value in cancer care, some types of resource-intensive therapies may need to be reconsidered. One such treatment may be hyperthermic intraperitoneal chemotherapy, which showed no benefit during surgery for colorectal cancer confined to the peritoneum in the PRODIGE 7...
Expert Point of View: Charles G. Drake, MD, PhD and Hatem H. Soliman, MD
Formal discussant of the GeparNuevo presentation, Charles G. Drake, MD, PhD, of the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, New York, said, “It is important that neoadjuvant immunotherapy combinations are being studied. There is a lot of enthusiasm for...
Expert Point of View: Daniel George, MD, Robert J. Motzer, MD, and Paul Russo, MD
Formal discussant of the CARMENA trial, Daniel George, MD, of Duke University Medical Center, Durham, North Carolina, had reservations about the broad application of these results. “CARMENA was designed to reassess the value and role of nephrectomy in patients who present with metastatic renal...
The Raven
The call from the dermatologist came at noon on Good Friday, just after my wife left with our two young daughters for a week on her family’s tree farm in Northern Michigan. I was on call for the hospital inpatient leukemia service, so I could not join them. When the dermatologist solemnly began,...
Minimal Residual Disease Testing in AML: Still a Shifting Target
Testing for minimal residual disease (MRD) has become an established part of the management of acute lymphoblastic leukemia (ALL), but in acute myeloid leukemia (AML), the technology still warrants validation. To address issues and set new standards, the European LeukemiaNet Working Party recently ...
EHA 2018: Ruxolitinib Reduces Risk of Thrombosis, Death in Patients With Polycythemia Vera
A new comparison study showed that among polycythemia vera patients who were resistant or intolerant to hydroxyurea, those treated with ruxolitinib (Jakavi) had a significantly reduced risk of thrombosis and death compared to those who received best available therapy. The study findings are based...
EHA 2018: Single-Agent Quizartinib vs Chemotherapy in Relapsed or Refractory AML
Results from the phase III QuANTUM-R study of single-agent quizartinib in relapsed or refractory acute myeloid leukemia (AML) were presented by Cortes et al at the 23rd Annual Congress of the European Hematology Association (EHA) (Abstract LB2600). Study Findings QuANTUM-R study results showed...
Expert Point of View: Colin D. Weekes, MD, PhD and Andrew Epstein, MD
Colin D. Weekes, MD, PhD, of Massachusetts General Hospital and Harvard Medical School, called the results of the PRODIGE trial “practice-changing.” Dr. Weekes was the invited discussant of the study and was interviewed by The ASCO Post. “The magnitude of effect is beyond what we have ever seen in...
FDA Clears Expanded Indication of Scalp-Cooling System
Paxman’s advanced scalp-cooling system has now been cleared by the US Food and Drug Administration (FDA) for use during treatment of patients with solid tumors. The system is now indicated to reduce the likelihood of chemotherapy-induced alopecia in cancer patients with solid tumors such as...
ASCO Guideline for Geriatric Oncology: Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy
As reported in the Journal of Clinical Oncology by Supriya G. Mohile, MD, of the University of Rochester Medical Center, and colleagues, ASCO has produced a guideline on the practical assessment and management of vulnerabilities in geriatric patients receiving chemotherapy. To develop the...
AMA Releases New Physician Guide on Caring for the Caregiver
Every day in their treatment rooms, physicians encounter individuals who are making profound sacrifices to help a loved one who is seriously ill, often at the expense of their own well-being. To help physicians understand the day-to-day challenges and risk of burnout faced by informal caregivers,...
Study Finds Breast Cancer Survivors Are Not Getting Recommended Number of Mammograms Postsurgery
Breast cancer survivors are not getting the recommended level of screening postsurgery, according to a study by Ruddy et al in JNCCN–Journal of the National Comprehensive Cancer Network. The study was led by Kathryn Ruddy, MD, MPH, Director of Cancer Survivorship for the Department of...
Opportunities, Issues, and Challenges for Biosimilars in Oncology
In an article in The New England Journal of Medicine, Lyman et al reviewed opportunities, issues, and challenges posed by the advent of biosimilar medications, focusing on biosimilars in cancer treatment. Although these agents could help to meet the health-care goals of high quality care with cost...
Barbara L. McAneny, MD, Inaugurated as 173rd President of the AMA
Barbara L. McAneny, MD, an oncologist from Albuquerque, has been sworn in as the 173rd President of the American Medical Association (AMA). She will focus her tenure on the AMA’s three strategic arcs: attacking the dysfunction in health care by removing obstacles and barriers that interfere...
ESMO Emphasizes Importance of Cancer on the Global Health Agenda at the 71st World Health Assembly
At the 71st World Health Assembly in Geneva, the European Society for Medical Oncology (ESMO) delivered two statements positioning cancer as a priority on the global agenda of the World Health Organization (WHO). Presenting its recommendations for action to the international community,...
ASCO Clinical Practice Guideline Focused Update: Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer
As reported by Neelima Denduluri, MD, of US Oncology Network, Virginia Cancer Specialists, and colleagues in the Journal of Clinical Oncology, ASCO has issued a focused update on the clinical practice guideline on optimal chemotherapy and targeted therapy in early breast cancer. To develop the...
Cancer Prevention Report Shows Consensus Among Global Experts on 10 Steps to Reduce Risk
An internationally released comprehensive analysis of research on lifestyle factors and cancer prevention confirms the critical links between cancer diagnoses and diet, physical activity, and weight. Independent experts from across the globe reviewed decades of scientific evidence to develop the...
AUA 2018: Finasteride Reduces Risk of Prostate Cancer and Is Safe, Long-Term Results Show
Twenty-five years after it opened for enrollment, the Prostate Cancer Prevention Trial (PCPT) has delivered a final verdict: finasteride, a common hormone-blocking drug, reduces men's risk of getting prostate cancer without increasing their risk of dying from the disease. Initial study...
Surveillance Intensity Not Associated With Earlier Detection of Recurrence or Improved Survival in Patients With Colorectal Cancer
A national retrospective study led by researchers at The University of Texas MD Anderson Cancer Center found no association between intensity of posttreatment surveillance and detection of recurrence or overall survival (OS) in patients with stage I, II, or III colorectal cancer. Published by...
ASCO’s TAPUR Study Website Now Features Updates on Patient Cohort Expansions and Closures
ASCO’S TARGETED Agent and Profiling Utilization Registry (TAPUR) Study now provides a full list of patient cohort expansions and closures on its website. Based on treatment responses in stage I, patient cohorts are either expanded to stage II for further study and identification of a signal or...
Spotlight on Women Who Conquer Cancer
WOMEN WHO CONQUER CANCER is a group dedicated to advancing cancer research by supporting young women researchers early in their careers through Conquer Cancer Foundation of ASCO Young Investigator Awards (YIAs). These 1-year grants give promising researchers the boost they need to get started on...
Resources to Help You Understand What Right-to-Try Legislation Means for Practices, Patients
WITH CONGRESS having recently passed federal “right-to-try” (RTT) legislation, ASCO has developed a suite of educational resources that will help members understand the impact of this law on cancer care and individuals with cancer. Educational resources include: Podcast THE LATEST ASCO in Action...
Expert Point of View: Oliver Dorigo, MD, PhD
COMMENTING ON the study, invited discussant Oliver Dorigo, MD, PhD, of Stanford University, said that tumor size and disease site are useful clinical parameters for predicting nonresponse to immunotherapy and should be considered when selecting and “unselecting” patients for immunotherapy...
Quick Takes From Original Research Presented at the 2018 NCCN Annual Conference
THE QUANTITY of original research presented at the National Comprehensive Cancer Network® (NCCN®) Annual Conference has been growing, and at the 2018 meeting, 121 researchers presented their work. The ASCO Post captured some of the findings for this report. Blood Markers Correlate With Anti–PD-1...
Durable Responses Observed With Novel Oncolytic Therapy in Recurrent Glioma
IN A PILOT study of recurrent glioma, 26% of patients treated with the optimal dose of vocimagene amiretroprepvec (aka Toca 511), a novel oncolytic virus therapy, achieved durable, long-term responses and remained alive 3 or more years later. This outcome far exceeded “historical benchmarks” for...
Expert Point of View: Sarah Blair, MD
SARAH BLAIR, MD, a breast surgeon at the University of California San Diego, noted that lymphedema remains a significant clinical problem, although the rates of lymphedema are decreasing, as fewer full axillary node dissections are performed. “This study utilizes bioimpedance spectroscopy, a...
Early Detection and Intervention Reduce Breast Cancer–Related Lymphedema
A NEW STUDY has found that early detection along with a simple intervention can be highly effective in preventing breast cancer–related lymphedema for at-risk women. According to data presented at the 2018 Annual Meeting of the American Society of Breast Surgeons,1 82% of women identified at an...
Studies Challenge Relevance of Genetic Testing Guidelines for Breast Cancer
NEW RESEARCH suggests that current genetic testing guidelines for breast cancer are far too restrictive, excluding nearly half of high-risk patients. According to a pair of studies presented at the 2018 American Society of Breast Surgeons (ASBrS) Annual Meeting, women with breast cancer who did not ...
Expert Point of View: Carla S. Fisher, MD
CARLA S. FISHER, MD, Associate Professor of Surgery at Indiana University School of Medicine, Indianapolis, underscored the importance of these data in informing treatment decisions given the difficult trade-off patients can face. “By analyzing a large group of patients treated in the modern era, ...
Geriatric Assessment Improves Communication Between Oncologists and Older Patients
A FEDERALLY FUNDED randomized study demonstrated that use of geriatric assessment in the routine care of older adults with advanced cancer significantly improved doctor-patient communication about age-related concerns as well as patient satisfaction with the communication. The study was presented...
Expert Point of View: Bruce Johnson, MD, FASCO
“PRECISION MEDICINE is driving the most exciting and powerful advances in cancer care today, particularly in lung cancer. It’s encouraging to see that next-generation genetic testing tools can help physicians and their patients get the crucial genomic information needed to make treatment decisions, ...
Decision-Analytic Model Finds Upfront, Comprehensive Genetic Testing in Advanced Lung Cancer Is Cost-Efficient
AN ECONOMIC model comparing different types of genetic testing in metastatic non–small cell lung cancer (NSCLC) found using next-generation sequencing to test for all known lung cancer–related gene changes at the time of diagnosis was less costly and faster than sequentially testing one or a...
Expert Point of View: Bruce Johnson, MD, FASCO
ASCO PRESIDENT Bruce E. Johnson, MD, FASCO, commented on these study findings during the press briefing. “This study adds to a growing body of knowledge showing the value of integrating patient-reported outcomes into routine oncology practice for symptom monitoring that a wide variety of our...
Mobile and Sensor Technology May Lead to Reduced Symptoms of Head and Neck Cancer and Its Treatment
A RANDOMIZED clinical trial evaluating the use of mobile and sensor technology to remotely monitor symptoms in patients receiving radiation therapy for head and neck cancer found that use of this technology reduced the severity of symptoms related to cancer and its treatment compared with usual...
Expert Point of View: John Heymach, MD, PhD, and Leena Gandhi, MD
“THIS STUDY represents a true milestone in the field of lung cancer. For the first time, the vast majority of patients with non–small cell lung cancer (NSCLC) can receive immunotherapy with pembrolizumab (Keytruda),” said ASCO expert John Heymach, MD, PhD, of MD Anderson Cancer Center, Houston,...
Immunotherapy Benefits Survival, Improves Safety, vs Platinum-Based Chemotherapy for PD-L1–Expressing NSCLC
IMMUNOTHERAPY WITH pembrolizumab (Keytruda) improved overall survival compared with investigator’s choice of platinum-based chemotherapy as first-line treatment for patients with advanced non–small cell lung cancer (NSCLC) in the KEYNOTE-042 trial. Median overall survival was improved by 4 to 8...
‘Pearls of Wisdom’ for Leadership and Success in Academic Medicine Gathered Over a 35-Year Career
Dr. Hayes, ASCO President 2016–2017, is Professor of Internal Medicine; Stuart B. Padnos Professor in Breast Cancer; and Clinical Director of the Breast Oncology Program at the University of Michigan Comprehensive Cancer Center, Ann Arbor. AS I COMPLETE my 3-year term as ASCO President, I am...
Adherence to Oral Anticancer Treatment: Priorities in Lymphoma and CLL
ADVANCES IN cancer treatment have been nothing short of breathtaking in recent years. Among the most important has been the advent of effective oral therapies, marking a significant change in the way many patients receive treatment and in the oversight required by the cancer care team. As with...
Expert Point of View: Lisa Carey, MD, and Dawn Hershman, MD, FASCO
LISA CAREY, MD, the Richardson and Marilyn Jacobs Preyer Distinguished Professor in Breast Cancer Research at the University of North Carolina, Chapel Hill, commented as the invited discussant for TAILORx, and Dawn L. Hershman, MD, FASCO, Professor of Medicine and Epidemiology and Leader of the...
TAILORx: Endocrine Therapy Alone Is Sufficient for Most Patients With ‘Intermediate-Risk’ Breast Cancer
THE HIGHLY ANTICIPATED results of the phase III TAILORx study are in—and they indicate that the vast majority of patients with “intermediate-risk” early-stage breast cancer can forgo chemotherapy. “Our study shows that chemotherapy may be avoided in about 70% of women with hormone...
Hearing Loss
The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Phase I Study of ERK1/2 Inhibitor in Advanced Solid Tumors
Ulixertinib (BVD-523) is an ERK1/2 kinase inhibitor with potent preclinical activity in BRAF- and RAS-mutant cell lines. Now, a multicenter phase I study investigating its safety and efficacy in the treatment of patients with advanced solid tumors has found that ulixertinib has an acceptable...
When Patients Are Open to Lifestyle Changes: Take Advantage of ‘Unique Window of Opportunity'
Colon cancer survivors who followed guidelines for healthy eating, maintaining a healthy weight, and staying physically active had higher 5-year survival rates than those who did not adhere to those guidelines, according to a study among 992 patients treated with stage III colon cancer.1 The 5-year ...
Following Guidelines for Healthy Eating and Physical Activity May Improve Survival in Patients Treated for Colon Cancer
Following guidelines for proper nutrition, maintaining a healthy weight, and staying physically active may improve survival among patients treated for colon cancer, according to the results of a study with nearly 1,000 patients followed for a median of 7 years.1 “The study suggests that if...
FDA Approves Biosimilar to Pegfilgrastim to Reduce Risk of Infection During Myelosuppressive Chemotherapy
On June 4, the U.S. Food and Drug Administration (FDA) approved pegfilgrastim-jmdb (Fulphila) as the first biosimilar to pegfilgrastim (Neulasta) to decrease the chance of infection as suggested by febrile neutropenia in patients with nonmyeloid cancer who are receiving myelosuppressive...
Tai Chi for the Treatment of Insomnia in Breast Cancer Survivors
Underrecognized and inadequately managed, insomnia is a significant burden for many cancer survivors. Often persistent over several years following diagnosis and treatment, sleep problems negatively affect quality of life and elevate the risk of depression and anxiety. In this installment of The...
